RESUMO
BACKGROUND: Prostate cancer cells produce high levels of the serine protease Prostate-Specific Antigen (PSA). PSA is enzymatically active in the tumor microenvironment but is presumed to be enzymatically inactive in the blood due to complex formation with serum protease inhibitors α-1-antichymotrypsin and α-2-macroglobulin (A2M). PSA-A2M complexes cannot be measured by standard ELISA assays and are also rapidly cleared from the circulation. Thus the exact magnitude of PSA production by prostate cancer cells is not easily measured. The PSA complexed to A2M is unable to cleave proteins but maintains the ability to cleave small peptide substrates. Thus, in advanced prostate cancer, sufficient PSA-A2M may be in circulation to effect total A2M levels, levels of cytokines bound to A2M and hydrolyze small circulating peptide hormones. METHODS: Total A2M levels in men with advanced prostate cancer and PSA levels above 1000 ng/mL were measured by ELISA and compared to controls. Additional ELISA assays were used to measure levels of IL-6 and TGF-beta which can bind to A2M. The ability of PSA-A2M complexes to hydrolyze protein and peptide substrates was analyzed ± PSA inhibitor. Enzymatic activity of PSA-A2M in serum of men with high PSA levels was also assayed. RESULTS: Serum A2M levels are inversely correlated with PSA levels in men with advanced prostate cancer. Il-6 Levels are significantly elevated in men with PSA >1000 ng/mL compared to controls with PSA <0.1 ng/mL. PSA-A2M complex in serum of men with PSA levels >1000 ng/mL can hydrolyze small fluorescently labeled peptide substrates but not large proteins that are PSA substrates. PSA can hydrolyze small peptide hormones like PTHrP and osteocalcin. PSA complexed to A2M retains the ability to degrade PTHrP. CONCLUSIONS: In advanced prostate cancer with PSA levels >1000 ng/mL, sufficient PSA-A2M is present in circulation to produce enzymatic activity against circulating small peptide hormones. Sufficient PSA is produced in advanced prostate cancer to alter total A2M levels, which can potentially alter levels of a variety of growth factors such as IL-6, TGF-beta, basic FGF, and PDGF. Alterations in levels of these cytokines and proteolytic degradation of small peptide hormones may have profound effect on host-cancer interaction.
Assuntos
Calicreínas/sangue , Osteocalcina/sangue , Proteína Relacionada ao Hormônio Paratireóideo/sangue , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , alfa-Macroglobulinas/metabolismo , Ácidos Borônicos/farmacologia , Estudos de Casos e Controles , Feminino , Humanos , Calicreínas/antagonistas & inibidores , Masculino , Peptidomiméticos/farmacologia , Antígeno Prostático Específico/antagonistas & inibidores , Neoplasias da Próstata/patologia , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
BACKGROUND: We previously identified ovostatin 2 (OVOS2) as a new candidate gene for cutaneous malignant melanoma (CMM) in a Chinese population. In this study, we aimed to investigate the exact role of OVOS2 in cell proliferation, invasion, and tumorigenesis of melanoma A375 cells. METHODS: The downregulation of OVOS2 expression was performed using lentiviral vectors with specific shRNA. The effects of OVOS2 expression on cell proliferation, cell cycle, cell migration, cell invasion, and potential of tumorigenesis were further investigated. RESULTS: The downregulation of OVOS2 significantly suppressed the proliferation of A375 cells and led to a G2/M phase block. The transwell cell migration assay showed that the reduced expression of OVOS2 also significantly inhibited the transmigration of A375 cells. The western blot results showed downregulated expression of p-FAK, p-AKT, and p-ERK. This was accompanied by the upregulated epithelial phenotypes E-cadherin and ß-catenin, and downregulated expression of mesenchymal phenotype N-cadherin after OVOS2 knockdown. The transplantation tumor experiment in BALB/C nude mouse showed that after an observation period of 32 days, the growth speed and weight of the transplanted tumors were significantly suppressed in the BALB/c nude mice subcutaneously injected with OVOS2 knocked-down A375 cells. CONCLUSION: The inhibition of OVOS2 had significant suppressive effects on the proliferation, motility, and migration capabilities of A375 cells, suggesting a crucial promotive role of OVOS2 in the pathogenesis and progression of CMM. The involved mechanisms are at least partly associated with the overactivation of FAK/MAPK/ERK and FAK/PI3K/AKT signals.
Assuntos
Carcinogênese/metabolismo , Movimento Celular/fisiologia , Proliferação de Células/fisiologia , Melanoma/metabolismo , Invasividade Neoplásica/fisiopatologia , Neoplasias Cutâneas/metabolismo , alfa-Macroglobulinas/metabolismo , Animais , Apoptose/fisiologia , Carcinogênese/patologia , Ciclo Celular/fisiologia , Linhagem Celular Tumoral , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Melanoma/patologia , Camundongos Endogâmicos BALB C , Camundongos Nus , Invasividade Neoplásica/patologia , Transplante de Neoplasias , RNA Mensageiro/metabolismo , Distribuição Aleatória , Neoplasias Cutâneas/patologia , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/genética , Melanoma Maligno CutâneoRESUMO
OBJECTIVE: Alpha2-macroglobulin (alpha2M) is an acute phase protein released to the serum upon challenges such as cardiac hypertrophy and infarction. Here we report on the role of alpha2M in the induction of hypertrophic cell growth, contractile responsiveness of rat ventricular cardiomyocytes, and on the underlying extracellular regulated kinase 1,2 (ERK1,2) and phosphoinositide 3-kinase (PI3-kinase)/Akt pathways. METHODS: Cell volume and cross-sectional areas were assessed as parameters of hypertrophic growth, and real time RT-PCR for the analysis of hypertrophy-related genes was performed. Protein synthesis was analyzed by 14C-phenylalanine incorporation. Activation of ERK1,2, PI3-kinase and Akt was assessed by immunohistochemical analysis of phosphorylated proteins. Contractile responsiveness was investigated by determination of cell shortening following electrical field stimulation. Intracellular calcium concentration [Ca2+]i was determined by fluo-3 microfluorometry. RESULTS: Treatment of ventricular cardiomyocytes for 24 h with alpha2M significantly increased cell volume and protein synthesis as well as expression of hypertrophy-associated genes [brain natriuretic protein (BNP), beta-myosin heavy chain (beta-MHC), myosin light chain-2 (MLC-2), atrial natriuretic factor (ANF), and skeletal alpha-actin]. Comparable effects were achieved by treatment of cells with an antibody directed against the alpha2M-receptor LDL receptor-related protein-1 (LRP-1) and counteracted upon coincubation with receptor-associated protein (RAP), suggesting an involvement of alpha2M-LRP-1 signalling. Furthermore, alpha2M treatment increased sarcoplasmic reticulum Ca2+-ATPase (SERCA-2a) expression, diastolic and systolic [Ca2+]i, and contractile responsiveness after electrical stimulation. Shortly after alpha2M stimulation, activation of ERK1,2, Akt, and PI3-kinase pathways was observed. Consequently, alpha2M-induced protein synthesis was inhibited upon treatment with the ERK1,2 inhibitor UO126 as well as by LY294002 and wortmannin, which inhibit PI3-kinase, and by rapamycin, which inhibits mammalian target of rapamycin (mTOR) downstream of Akt. CONCLUSIONS: Our data show that alpha2M induces hypertrophic cell growth in rat ventricular cardiomyocytes via ERK1,2 and PI3-kinase/Akt and improves cardiac cell function.
Assuntos
Cardiomegalia/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/fisiologia , alfa-Macroglobulinas/metabolismo , Androstadienos/farmacologia , Animais , Butadienos/farmacologia , Cálcio/metabolismo , Células Cultivadas , Cromonas/farmacologia , Ativação Enzimática , Imuno-Histoquímica , Masculino , Morfolinas/farmacologia , Nitrilas/farmacologia , Fenilalanina/metabolismo , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/metabolismo , Sirolimo/farmacologia , Wortmanina , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/farmacologiaRESUMO
The activity and plasma clearance of transforming growth factor (TGF)-beta are known to be regulated by activated alpha2-macroglobulin (alpha2M*). This has been implicated in pathophysiological processes, but no small molecule compounds have been reported to modulate TGF-beta activity by affecting the interaction of TGF-beta and alpha2M*. Here, we demonstrate that fatty acids are capable of inhibiting complex formation of TGF-beta isoforms and alpha2M* as demonstrated by nondenaturing and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This is dependent on carbon chain length (C20, C18, C16, C14 > C12 > C10), degree of unsaturation (polyunsaturated > saturated), and TGF-beta isoforms (TGF-beta1 > TGF-beta2 > TGF-beta3). Arachidonic acid, which is one of the most potent inhibitors, is also capable of dissociating TGF-beta-alpha2M* complexes, but higher concentrations are required. Arachidonic acid appears to inhibit TGF-beta-alpha2M* complex formation by binding specifically to alpha2M* as demonstrated by gel filtration chromatography. Arachidonic acid reverses the inhibitory effect of alpha2M* on TGF-beta binding, TGF-beta-induced growth inhibition, and TGF-beta-induced transcriptional activation in mink lung epithelial cells and affects plasma clearance of TGF-beta-alpha2M* complexes in mice. These results show that fatty acids are effective modulators of TGF-beta activity and plasma clearance and may be useful in treating human diseases through their effects on the interaction of TGF-beta and alpha2M*.
Assuntos
Ácidos Graxos/farmacologia , Fator de Crescimento Transformador beta/antagonistas & inibidores , Fator de Crescimento Transformador beta/sangue , Animais , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Substâncias Macromoleculares , Camundongos , Vison , Modelos Biológicos , Isoformas de Proteínas/metabolismo , Receptores de Fatores de Crescimento Transformadores beta/metabolismo , Ativação Transcricional/efeitos dos fármacos , Fator de Crescimento Transformador beta/metabolismo , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/metabolismoRESUMO
We have studied the induction of cyclooxygenase-2 (COX-2) in macrophages consequent to ligating the alpha(2)-macroglobulin (alpha(2)M) signalling receptor (alpha(2)MSR) with receptor-recognized forms of alpha(2)M (alpha(2)M*). Macrophage stimulation with alpha(2)M* increased total cellular and nuclear COX-2 two- to threefold. The maximal increase in COX-2 occurred at a ligand concentration of 50-100 pM and after 2 h. Modulation of intracellular Ca(2+) levels or incubation of [35S] methionine-labelled macrophages with actinomycin D, prior to treatment with alpha(2)M*, markedly reduced the induction of total cellular and nuclear COX-2. Protein kinase C (PKC) or phospholipase A(2) (PLA(2)) inhibition in alpha(2)M*-stimulated macrophages or inhibition of the p21(ras)-dependent mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI 3-kinase) signalling pathways also significantly reduced alpha(2)M*-induced total cellular and nuclear COX-2 expression. Thus, COX-2 induction is dependent on cPLA(2) activity, Ca(2+) mobilization, and PKC activity and requires participation of both the p21(ras)-dependent MAPK and PI 3-kinase signalling pathways. COX-2 activation may mediate alpha(2)M*-induced mitogenesis, which we have previously observed in this and other cell types.
Assuntos
Isoenzimas/biossíntese , Proteína-1 Relacionada a Receptor de Lipoproteína de Baixa Densidade/fisiologia , Macrófagos/enzimologia , Prostaglandina-Endoperóxido Sintases/biossíntese , Animais , Cálcio/fisiologia , Núcleo Celular/metabolismo , Células Cultivadas , Ciclo-Oxigenase 2 , Dactinomicina/farmacologia , Inibidores Enzimáticos/farmacologia , Sistema de Sinalização das MAP Quinases , Camundongos , Inibidores da Síntese de Ácido Nucleico/farmacologia , Fosfatidilinositol Diacilglicerol-Liase , Inibidores de Fosfoinositídeo-3 Quinase , Fosfolipases A/antagonistas & inibidores , Proteína Quinase C/antagonistas & inibidores , Proteínas Proto-Oncogênicas p21(ras)/fisiologia , Fosfolipases Tipo C/antagonistas & inibidores , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/farmacologiaRESUMO
The cross-talk between the signal transduction of simultaneous acting cytokines largely determines the final impact of cytokines on their target genes. Both NF-kappaB and STAT3 are transcription factors well known to be activated by many stimuli and to mediate transcriptional activation by binding to specific enhancer sequences. In this study, it is analyzed how IL-1beta inhibits IL-6-induced transcriptional activation of the alpha(2)-macroglobulin promoter. It is shown that IL-1beta prevents STAT3 binding to the two STAT3-responsive sites within the alpha(2)-macroglobulin promoter by association of IL-1beta-activated NF-kappaB to this region. The observation that inhibition of IL-6-induced transcriptional activation of this promoter by IL-1beta is reversed by cotransfection with I-kappaBalpha provides evidence that NF-kappaB activation by IL-1beta is responsible for inhibition of IL-6-mediated trans activation of the alpha(2)-macroglobulin gene. Accordingly, cotransfection of the NF-kappaB subunits p50 or p65 themselves inhibited activation of the alpha(2)-macroglobulin promoter by IL-6. Introduction of point mutations in each of the two NF-kappaB sites overlapping the two STAT3 binding sites within the alpha(2)-macroglobulin promoter provides evidence that each of these two sites counteracts transcriptional activation via STAT3. Most interestingly, at least one functional NF-kappaB consensus site is essential for the IL-6-induced transcriptional activation of the alpha(2)-macroglobulin promoter. Additional data are provided indicating that the activation of NF-kappaB by IL-1beta is also responsible for the inhibition of other IL-6-inducible genes, such as the alpha(1)-antichymotrypsin gene as well as the suppressor of cytokine signaling 3 gene, suggesting a more general relevance of this mechanism for transcriptional regulation.
Assuntos
Interleucina-1/fisiologia , Interleucina-6/antagonistas & inibidores , Interleucina-6/fisiologia , NF-kappa B/metabolismo , Proteínas Repressoras , Fatores de Transcrição , Ativação Transcricional/imunologia , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/biossíntese , Animais , Sequência de Bases , Ligação Competitiva/genética , Ligação Competitiva/imunologia , Proteínas de Ligação a DNA/antagonistas & inibidores , Proteínas de Ligação a DNA/metabolismo , Humanos , Interleucina-6/genética , Masculino , Dados de Sequência Molecular , Regiões Promotoras Genéticas/imunologia , Biossíntese de Proteínas , Ratos , Ratos Wistar , Fator de Transcrição STAT3 , Transdução de Sinais/genética , Transdução de Sinais/imunologia , Proteína 3 Supressora da Sinalização de Citocinas , Proteínas Supressoras da Sinalização de Citocina , Transativadores/antagonistas & inibidores , Transativadores/metabolismo , Células Tumorais Cultivadas , Regulação para Cima/imunologia , alfa-Macroglobulinas/genéticaRESUMO
Uric acid (2,6,8 trioxopurine), the end product of purine metabolism in mammalian systems, has shown a wide range of antioxidant properties including scavenging of hydroxyl radical and singlet oxygen. In this study we show that in the presence of visible light, uric acid disrupted caprine alpha-2-macroglobulin (alpha(2) M) structure and antiproteolytic function in vitro. Proteinase cleaves the bait region of caprine inhibitor inducing major conformational changes and entrapping the enzyme within its molecular cage. In contrast to native alpha(2) M, modified antiproteinase lost half of its antiproteolytic potential within 4 hours of uric acid exposure. The changes in uv-absorption spectra of the treated protein suggested possible spatial rearrangement of subunits or conformational change. Analysis of the mechanism by which alpha(2) M was inactivated revealed that the process was dependent on generation of superoxide anion and hydrogen peroxide. Our findings suggest that antiproteolytic activity of caprine alpha(2) M could be compromised via oxidative modification mediated by uric acid. Moreover, low concentrations of alpha(2) M were found to stimulate superoxide production by some unknown mechanism.
Assuntos
Ácido Úrico/farmacologia , alfa-Macroglobulinas/antagonistas & inibidores , Motivos de Aminoácidos , Animais , Eletroforese em Gel de Poliacrilamida , Cabras , Peróxido de Hidrogênio/metabolismo , Luz , Oxirredução , Fotoquímica , Conformação Proteica/efeitos dos fármacos , Espectrofotometria Ultravioleta , Superóxidos/metabolismo , alfa-Macroglobulinas/química , alfa-Macroglobulinas/farmacologia , alfa-Macroglobulinas/efeitos da radiaçãoRESUMO
alpha2-macroglobulin (alpha2M) is a broad-spectrum proteinase inhibitor and one of the major plasma proteins in humans. Activated phagocytes (especially granulocytes) generate large amounts of oxidants of the HOCI- and chloramine-type that release the mild nonradical, excited (light-emitting) oxidant singlet oxygen ((1)O2). These oxidants have been shown to inactivate several specific serine protease inhibitors in human blood [e.g., alpha1-antitrypsin or alpha2-antiplasmin (plasmin inhibitor)]. The studies reported here demonstrate that nonradical oxidants also inactivate plasmatic alpha2M. The effective dose for 50% inactivation (ED50) of plasmatic alpha2M is similar to that for plasmatic alpha2-antiplasmin. Chloramines are about 1,000-fold more effective than hydrogen peroxide (ED50)=0.75 micromol chloramine T/50 microl plasma). Serine protease-serine protease inhibitor complexes are resistant to oxidants. In contrast, here it is shown that alpha2-macroglobulin, even after binding to serine proteases is sensitive to oxidation, the captured protease is released from the protease/alpha2M complex. This is the first time that oxidative inactivation of a complexed (i.e., bound to a target protease) human protease inhibitor has be shown. The (1)O2 inhibitors methionine, cysteine, cystine, or ascorbate-in contrast to the oxy-radical scavengers mannitol, superoxide dismutase, or catalase-antagonize the chloramine/NaOCl-mediated inactivation of both uncomplexed and complexed alpha2M. Thus, the oxidant involved here is of nonradicalic nature and has reaction characteristics of (1)O2. For the inhibitory function, critical oxidizable methionines or the internal thiol-ester might be targets for (1)O2. Consequently, alpha2M can also be considered a carrier for proteases, since the alpha2M-complexed proteases regain full activity in an oxidative environment. In local areas of inflammation or thrombolysis, activated phagocytes could create microenvironments of uncontrolled protease activity by generation of (1)O2.
Assuntos
Oxigênio/farmacologia , alfa-Macroglobulinas/efeitos dos fármacos , Cloraminas/farmacologia , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Humanos , Peróxido de Hidrogênio/farmacologia , Inibidores de Proteases/metabolismo , Oxigênio Singlete , alfa 2-Antiplasmina/efeitos dos fármacos , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/metabolismoRESUMO
Interleukin-6 is involved in the regulation of many biological activities such as gene expression, cell proliferation, and differentiation. The control of the termination of cytokine signaling is as important as the regulation of initiation of signal transduction pathways. Three families of proteins involved in the down-regulation of cytokine signaling have been described recently: (i) SH2 domain-containing protein-tyrosine phosphatases (SHP), (ii) suppressors of cytokine signaling (SOCS), and (iii) protein inhibitors of activated STATs (PIAS). We have analyzed the interplay of two inhibitors in the signal transduction pathway of interleukin-6 and demonstrate that the tyrosine phosphatase SHP2 and SOCS3 do not act independently but are functionally linked. The activation of one inhibitor modulates the activity of the other; Inhibition of SHP2 activation leads to increased SOCS3-mRNA levels, whereas increased expression of SOCS3 results in a reduction of SHP2 phosphorylation after activation of the interleukin-6 signal transduction pathway. Furthermore, we show that tyrosine 759 in gp130 is essential for both SHP2 and SOCS3 but not for SOCS1 to exert their inhibitory activities on interleukin-6 signal transduction. Besides SHP2, SOCS3 also interacts with the Tyr(P)-759 peptide of gp130. Taken together, our results suggest differences in the function of SOCS1 and SOCS3 and a link between SHP2 and SOCS3.
Assuntos
Antígenos CD/metabolismo , Interleucina-6/antagonistas & inibidores , Interleucina-6/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular , Glicoproteínas de Membrana/metabolismo , Proteínas Tirosina Fosfatases/metabolismo , Proteínas/fisiologia , Proteínas Repressoras , Fatores de Transcrição , Northern Blotting , Proteínas de Transporte/metabolismo , Núcleo Celular/metabolismo , Receptor gp130 de Citocina , Glutationa Transferase/metabolismo , Humanos , Immunoblotting , Fosforilação , Testes de Precipitina , Regiões Promotoras Genéticas , Ligação Proteica , Proteína Tirosina Fosfatase não Receptora Tipo 11 , Proteína Tirosina Fosfatase não Receptora Tipo 6 , Proteínas Tirosina Fosfatases/química , Proteínas/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , Proteínas Tirosina Fosfatases Contendo o Domínio SH2 , Transdução de Sinais , Proteína 1 Supressora da Sinalização de Citocina , Proteína 3 Supressora da Sinalização de Citocinas , Proteínas Supressoras da Sinalização de Citocina , Transfecção , Células Tumorais Cultivadas , Tirosina/química , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/genética , Domínios de Homologia de srcRESUMO
[formula: see text] A regio- and stereospecific total synthesis of (+/-)-methyl rishirilide B (2b), and (alpha)2-macroglobulin inhibitor, is described. A key feature of the synthetic plan was regiospecific construction of a hydroanthracenone intermediate through condensation of a phenylsulfonyl isobenzofuranone with a functionalized 2-cyclohexen-1-one. Introduction of the vicinal trans-hydroxyl groups in the densely functionalized A-ring was accomplished via a novel one-pot procedure that involved oxidation of enolate anions with the Davis reagent.
Assuntos
Antracenos/química , Antracenos/síntese química , Fibrinolíticos/síntese química , alfa-Macroglobulinas/antagonistas & inibidores , Hidrólise , Indicadores e Reagentes , Estereoisomerismo , Streptomyces/químicaRESUMO
The histidine at position 1106 of the C4B isotype of human complement is involved in catalyzing the covalent binding of the thioester to glycerol and water. By replacing the histidine with other residues, it was found that tyrosine is also capable of mediating the reaction. We propose that they act as nucleophiles by first attacking the thioester, upon activation, to form acyl intermediates, which subsequently react with the hydroxyl groups of glycerol or water. The monomeric alpha-macroglobulin, alpha 1I3 of the rat, was also studied. Unlike alpha 2-macroglobulin, which is a tetramer, alpha 1I3 has binding properties similar to those of C4A.
Assuntos
Complemento C4/metabolismo , Histidina/metabolismo , alfa-Macroglobulinas/metabolismo , Sequência de Aminoácidos , Animais , Sequência de Bases , Linhagem Celular , Clonagem Molecular , Complemento C4/química , Complemento C4/genética , DNA , Cobaias , Concentração de Íons de Hidrogênio , Ligação Proteica , Ratos , Proteínas Recombinantes/metabolismo , Ovinos , Compostos de Sulfidrila/metabolismo , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
Vibrio vulnificus, an opportunistic human pathogen, secretes a metalloprotease which has been suspected of being the causative factor for edematous skin lesions. The antibody against alpha-macroglobulin, the sole plasma inactivator of V. vulnificus metalloprotease, delayed clearance of the protease administered into dorsal skin, and increased the edema-forming ability of living bacterial cells. The derivative of the protease, which is resistant to the inactivating action of alpha-macroglobulin, was not excluded from the dorsal skin. Furthermore, the vibrio inoculated into the mammalian serum was found to produce the protease in adequate amounts. These results suggest that V. vulnificus secretes a metalloprotease into the interstitial-tissue space, resulting in the development of an edematous skin lesion, and that the protease is immediately inactivated by alpha-macroglobulin and subsequently excluded.
Assuntos
Metaloendopeptidases/biossíntese , Dermatopatias Bacterianas/etiologia , Vibrioses/etiologia , Vibrio/enzimologia , Vibrio/patogenicidade , Animais , Permeabilidade Capilar , Edema/etiologia , Cobaias , Humanos , Fragmentos Fab das Imunoglobulinas/farmacologia , Masculino , Metaloendopeptidases/antagonistas & inibidores , Infecções Oportunistas/etiologia , Infecção dos Ferimentos/etiologia , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/imunologia , alfa-Macroglobulinas/metabolismoRESUMO
Monoamine-activated alpha 2-macroglobulin (alpha 2M) has recently been shown to inhibit the growth and survival of cholinergic neurons of the basal forebrain (Liebl and Koo: J Neurosci Res 35:170-182, 1993). The mechanism of this inhibitory effect is believed to involve the regulation of growth factor activities by alpha 2M. The objectives of this study are to determine whether monoamine-activated alpha 2M can inhibit choline acetyltransferase (ChAT) activity of cholinergic basal forebrain neurons, and whether some common neurotrophins in the CNS can reverse the inhibition. This study demonstrates that both methylamine-activated alpha 2M (MA-alpha 2M) and serotonin-activated alpha 2M (5HT-alpha 2M) can dose-dependently suppress the expression of normal basal levels of ChAT activity in embryonic rat basal forebrain cells in vitro, while normal alpha 2M has little or no effect. As little as 0.35 microM monoamine-activated alpha 2M can suppress the ChAT activity, whereas either nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF), but not neurotrophin-3 (NT-3), stimulates ChAT expression of these cells. The addition of either NGF or BDNF to the alpha 2M-suppressed cells can increase ChAT activity back to its normal levels, while NT-3 can not. These results demonstrate that (1) monoamine-activated alpha 2M is a potent non-cytotoxic inhibitor of the ChAT activity in cholinergic basal forebrain neurons, and (2) NGF and BDNF are capable of not only stimulating the ChAT activity but can also specifically reverse the alpha 2M inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Monoaminas Biogênicas/farmacologia , Colina O-Acetiltransferase/antagonistas & inibidores , Fatores de Crescimento Neural/farmacologia , Neurônios/metabolismo , Prosencéfalo/citologia , alfa-Macroglobulinas/farmacologia , Animais , Fator Neurotrófico Derivado do Encéfalo , Células Cultivadas , Humanos , Proteínas do Tecido Nervoso/farmacologia , Neurônios/efeitos dos fármacos , Neurotrofina 3 , Ratos , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
Alpha-2-macroglobulin (alpha 2M) may function as a proteinase inhibitor in vivo. Levels of this protein are decreased in sepsis, but the reason these levels are low is unknown. Therefore, we analyzed the behavior of alpha 2M in a baboon model for sepsis. Upon challenge with a lethal (4 baboons) or a sublethal (10 baboons) dose of Escherichia coli, levels of inactivated alpha 2M (i alpha 2M) steadily increased, the changes being more pronounced in the animals that received the lethal dose. The rise in i alpha 2M significantly correlated with the increase of thrombin-antithrombin III, plasmin-alpha 2-antiplasmin, and, to a lesser extent, with that of elastase-alpha 1-antitrypsin complexes, raising the question of involvement of fibrinolytic, clotting, and neutrophilic proteinases in the inactivation of alpha 2M. Experiments with chromogenic substrates confirmed that thrombin, plasmin, elastase, and cathepsin G indeed had formed complexes with alpha 2M. Changes in alpha 2M similar to those observed in the animals that received E. coli occurred in baboons challenged with Staphylococcus aureus, indicating that alpha 2M formed complexes with the proteinases just mentioned in gram-positive sepsis as well. We conclude that alpha 2M in this baboon model for sepsis is inactivated by formation of complexes with proteinases, derived from activated neutrophils and from fibrinolytic and coagulation cascades. We suggest that similar mechanisms may account for the decreased alpha 2M levels in clinical sepsis.
Assuntos
Infecções por Escherichia coli/sangue , Inibidores de Proteases/sangue , alfa-Macroglobulinas/metabolismo , Animais , Coagulação Sanguínea/fisiologia , Modelos Animais de Doenças , Infecções por Escherichia coli/etiologia , Fibrinolisina/metabolismo , Fibrinólise/fisiologia , Neutrófilos/fisiologia , Elastase Pancreática/antagonistas & inibidores , Elastase Pancreática/sangue , Papio , Infecções Estafilocócicas/sangue , Infecções Estafilocócicas/etiologia , Trombina/metabolismo , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
The plasma contact system was studied in ascites and plasma from patients with gastrointestinal cancer and patients with liver failure. Our study demonstrates the presence of factor XII, factor XI, and prekallikrein and their main inhibitors in ascites and plasma from both patient groups. Both factor XII-like and plasma kallikrein-like activities were detected in the malignant ascites. The kallikrein-like activity in malignant ascites was found in complex with alpha 2-macroglobulin. In plasma samples from the patients functional values of factor XII and prekallikrein were decreased compared to controls. In benign ascites the proenzyme levels were significantly lower than in malignant ascites. Functional inhibition values in ascites and plasma from patients were unexpectedly high. Our findings indicate that the plasma contact system is activated in the ascites from cancer patients. Activation of the contact system generates vasoactive mediators, which may play a role in the accumulation of malignant ascites.
Assuntos
Ascite/metabolismo , Neoplasias Gastrointestinais/metabolismo , Falência Hepática/metabolismo , Idoso , Proteínas Sanguíneas/metabolismo , Proteínas Inativadoras do Complemento 1/metabolismo , Fator XI/metabolismo , Fator XII/metabolismo , Feminino , Neoplasias Gastrointestinais/sangue , Humanos , Immunoblotting , Calicreínas/antagonistas & inibidores , Falência Hepática/sangue , Masculino , Pessoa de Meia-Idade , Pré-Calicreína/metabolismo , Proteínas/metabolismo , alfa 1-Antitripsina/metabolismo , alfa-Macroglobulinas/antagonistas & inibidores , alfa-Macroglobulinas/metabolismoRESUMO
Recent experiments in vitro have shown that inhibition of human alpha 2-antiplasmin by a monoclonal antibody (MAb RWR) markedly enhances clot lysis by plasminogen activators. To extend these studies in vivo, we tested whether inhibition of clot or fibrin-bound alpha 2-antiplasmin by MAb RWR could enhance the lysis of a human clot by tissue-type plasminogen activator (t-PA) in a rabbit jugular vein thrombosis model. Compared with a saline placebo or a control antibody, MAb RWR significantly increased thrombolysis by endogenous plasminogen activator in rabbits to which no t-PA was administered (p less than 0.05). In rabbits that received t-PA, the combination of MAb RWR and t-PA caused significantly greater thrombolysis than equivalent doses of t-PA alone (p less than 0.05). However, compared with equipotent doses of t-PA alone, the combination of MAb RWR and t-PA did not increase the nonspecific consumption of fibrinogen. These experiments suggest that the combination of an alpha 2-antiplasmin inhibitor and a plasminogen activator could be a more potent thrombolytic strategy.
Assuntos
Coagulação Sanguínea , Fibrinolisina/antagonistas & inibidores , Fibrinolíticos/farmacologia , alfa-Macroglobulinas/antagonistas & inibidores , Animais , Anticorpos Monoclonais , Fibrinogênio/metabolismo , Fibrinolisina/metabolismo , Humanos , Coelhos , Ativador de Plasminogênio Tecidual/farmacologia , alfa 2-Antiplasmina/metabolismo , alfa-Macroglobulinas/metabolismoAssuntos
Artrite Reumatoide/enzimologia , Colagenase Microbiana/análise , Líquido Sinovial/enzimologia , Tripsina/farmacologia , Cromatografia em Gel , Ativação Enzimática/efeitos dos fármacos , Humanos , Colagenase Microbiana/antagonistas & inibidores , Colagenase Microbiana/metabolismo , Peso Molecular , Espectrofotometria Ultravioleta , alfa-Macroglobulinas/análise , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
Human alpha 2-macroglobulin (alpha 2M) rapidly lost functional and structural integrity in the course of a short-term incubation with either triggered neutrophils or eosinophils. In contrast to native alpha 2M, the modified antiproteinase was unable to bind neutrophil elastase or pancreatic elastase in a manner that restricted the enzymes' access to high molecular weight substrates. In addition to the complete loss of its antiproteolytic potential, the conformation of the dysfunctional inhibitor was radically altered and susceptible to further modification by exogenous proteinases as assessed by polyacrylamide gel electrophoresis. Analysis of the mechanism by which alpha 2M was inactivated by neutrophils revealed that the process was dependent on the generation of hypochlorous acid, an oxidant generated by the hydrogen peroxide-myeloperoxidase-chloride system. In contrast to the neutrophil, maximal eosinophil-dependent inactivation required the presence of physiologic concentrations of bromide and appeared to involve the generation of hypobromous acid. The ability of either hypochlorous acid or hypobromous acid to directly disrupt alpha 2M function and structure was confirmed under cell-free conditions. These results demonstrate that alpha 2M, an antiproteinase heretofore considered to be resistant to physiologic inactivation, could be destroyed by two populations of human phagocytes via oxidative modifications mediated by hypophalous acids.
Assuntos
Eosinófilos/metabolismo , Neutrófilos/metabolismo , alfa-Macroglobulinas/metabolismo , Sistema Livre de Células , Humanos , Técnicas In Vitro , Cinética , Oxirredução , Acetato de Tetradecanoilforbol/farmacologia , alfa-Macroglobulinas/antagonistas & inibidoresRESUMO
Pseudomonas aeruginosa alkaline protease (AP) has recently been shown to produce limited proteolysis of human gamma interferon (IFN-gamma) and thereby destroy the antiviral and macrophage-activating activities of the lymphokine. In the present study we describe some of the characteristics of Pseudomonas elastase (E) with regard to inactivation of human IFN-gamma. The inhibitory effect of E on IFN-gamma bioactivity differed from that of AP in that the direct effects of E were reduced in the presence of human serum. That this property of human serum was in large part attributable to the protease inhibitor alpha 2-macroglobulin (alpha 2-M) was suggested by the following observations: (i) methylamine treatment of serum reduced its effect on E, (ii) E interacted directly with alpha 2-M to induce a characteristic conformational change in the protease inhibitor, and (iii) preformed E-alpha 2-M complexes lacked IFN-gamma-degrading activity. Despite these findings, anti-E antiserum partially neutralized the effect that a Pseudomonas filtrate showed on IFN-gamma, suggesting that E contributes to the activity of bacterial filtrates. Treatment of IFN-gamma with E in the presence of a suboptimal concentration of AP resulted in an E dose-dependent inactivation of the lymphokine. Preformed E-alpha 2-M complexes, although ineffective by themselves at cleaving IFN-gamma, degraded the lymphokine, providing AP was also present in the reaction mixture. These data demonstrate that the destruction of small, biologically significant peptides by Pseudomonas proteases can involve protease-protease synergy that acts even in the presence of the serum protease inhibitor alpha 2-M.